Once-Weekly Weight Management 99% G-Lp1 Finished Peptides Cagrilintide 10mg 15mg 30mg Vials USA Warehouse Glxc-26801 Weight Loss Peptide Cagrilintide Reta Semag

• Customization: Available
• CAS No.: N/a
• Formula: N/a
• Model NO.: Cagri
• EINECS: N/a
• Type: Pharmaceutical Intermediates
• Appearance: Powder
• Quality: Technical
• Colour: White
• Name: N/a
• Mf: N/a
• MW: N/a
• CAS: N/a
• Packing: 10vials/Box
• Usage: for Research Use Only
• Suitable for: Elderly, Adult
• Transport Package: Customized Request
• Specification: 5mg/vial; 10mg/vial; 15mg/vial; 30mg/vial
• Trademark: RDG
• Origin: China
• Production Capacity: 50000vials

Product Description

Once-Weekly Weight Management 99% G-LP1 Finished Peptides Cagrilintide 10mg 15mg 30mg Vials USA Warehouse Glxc-26801 Weight Loss Peptide Cagrilintide Reta Semag

 

Product name	Reta
Appearance	White powder
Purity	99%
Storage	Keep in a cool, dry, dark location in a tightly sealed container or cylinder.
Shelf Life	24 Months

Application:

Novel weight loss peptides (Reta,Smag-TIDE,TZ,Cagrin,CagrinS)were approved wellness for weight loss. They are newest

class of  chemical products better known for its ability to improve blood sugar control. 

Obesity is a complex disease that occurs when an individual's weight is higher than what is considered healthy for his/her height.

According to the CDC, people with a body mass index (BMI) between 25 and 29.9 are considered overweight, and people with a

BMI of 30 or higher are considered obese.

Weight Loss peptides works in the treatment of obesity by targeting three different hunger regulating hormones:

1.GIP (gastric inhibitory peptide or glucose-dependent insulinotropic polypeptide) is an incretin hormone that is released from the

gut after eating. It stimulates the beta-cells in the pancreas to secrete.

2.G-LP-1r (glucagon-like peptide-1r) is also an incretin hormone that stimulates the beta-cells to secrete.

- glucagon is a hormone secreted from the alpha-cells in the pancreas. It stimulates glucose production in the liver and helps

maintain adequate plasma glucose concentrations.

The peptide has been nicknamed 'triple G' because it is an agonist of all three receptors.

Phase 2 clinical trial results published in The New England Journal of Medicine show weight loss peptides achieved up to 17.5%

mean weight reduction at 24 weeks in adults with obesity and overweight. In a secondary endpoint, retatrutide demonstrated a

mean weight reduction up to 24.2% at 48 weeks.

Weight loss pepides as an injection that are administered once-weekly.

In the research items,they showed glucose control and weight loss, type 2 diabetes mellitus (T2DM).
 

They can be just used for the research purpose.

Normally, They will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details,

please refer to the manual:Handling and Storage of Synthetic Peptides.


Benifits:

Semg&Cagris are a single agonist peptide ,Semg&Cagris  can be used for the research of obesity treatment or cravings

suppression,T2dm Therapies,and so on.

Tiz&Cagris are a Dual agonists peptide ,Tiz&Cagris can be used for the research of Anti-obesity or appetite Suppression and so

on.

Reta is a triple agonist peptide ,Reta can be used for the research of Anti-obesity,burn fat,boost energy.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details,

please refer to the manual:Handling and Storage of Synthetic Peptides.

What is Reta?

Reta is a synthetic peptide, known for its unique action as a triple receptor agonist. This peptide, also referred to by its code name

LY3437943, targets three key receptors: glucagon-like peptide-1 (G-LP-1r,GIP),and glucagon (GCG). Each of these receptors

plays an important role in regulating metabolism, with a particular focus on weight Loss,energy expenditure, and blood glucose

levels.

The compound is designed to activate these three receptors simultaneously, with special emphasis on GIP, to help manage

metabolic conditions like type 2 diabetes and support weight loss. Retatrutide is composed of 39 amino acids and is structurally

engineered to maintain stability and prolonged activity in the body. This design makes it an attractive candidate for improving

metabolic health and supporting weight management.

Reta's mode of action is what sets it apart from other peptides. Its ability to address multiple aspects of metabolic regulation could

offer significant benefits for individuals seeking to manage their weight or improve glycemic control.

Important details for researchers:

1.Synthetic design: Though primarily targeting GIP receptors, retatrutide has been designed to also activate G-LP-1r and GCG

receptors, enhancing its effects in regulating metabolism and supporting weight management.
 

2.Extended activity: The peptide includes a fatty acid component that enhances stability, allowing for less frequent dosing,

typically once a week.
 

3.Clinical trials: Retatrutide is being evaluated in Phase-3 clinical trials, primarily for its effectiveness in supporting weight loss,

with positive results in improving glycemic control and reducing body weight.
 

3.Regulatory status: Currently, the peptide is available for research purposes, though it has not yet been approved by regulatory

bodies such as the FDA.

For Research Purpose Only. Purchasing objects are required to be companies and labs, not for personal use.